Causes, Assessment and Management of Cesarean Scar Pregnancy

**Abstract**

Cesarean scar pregnancy (CSP) is on the rise worldwide due to the increasing rate of cesarean sections. It has been attributed to life threatening complications if not diagnosed early and managed aggressively. CSP is still a rare diagnosis, as available literature is mostly observational case series and few random controlled trials (RCT) to date. Treatment of CSP should be evidence based and focus on prevention of severe complications, conservation of fertility and maintaining women’s health and quality life. Despite this prominent increase, no universal treatment guidelines have been established till now, and the management of CSP in clinical practice is based on few available published literatures. Treatment should be individualized by using parameters such as hemodynamic status of the patient, beta-hCG levels, imaging features, the desire for future pregnancy and the surgeon’s skill. Current data does not support expectant management. In this article, we aim to find the pathophysiology, clinical presentation, most appropriate methods of diagnosis and treatment of CSP.

**Keywords:** Ectopic pregnancy; Previous cesarean scar; Cesarean scar pregnancy

**Introduction**

Cesarean scar pregnancy is rare but potentially life threatening type of ectopic pregnancy. It is a condition in which the conceptus implants in an iatrogenic cesarean scar in the uterus and is surrounded by uterine muscular fiber, scar tissue, and thin myometrium adjacent to the bladder. It can occur in women with a single previous cesarean delivery. CSP was first described by [1]. The incidence of CSP has been reported to be 1:1800-1:2216 of normal pregnancies and accounts for 6.1% of all ectopic pregnancies [2-5]. This rate is expected to rise in the future worldwide owing to increasing rates of cesarean deliveries and awareness of its pathology. During the last two decades ultrasonography diagnosis have improved and the techniques for uterine surgery has changed. In recent time the uterus is often closed in one layer, compared with the previous two-layer technique. These factors may play a role in the increasing prevalence of CSP. Vial et al. [6] proposed two different types of CSPs; Endogenous CSP (CSP type I) and Exogenous CSP (CSP type II). CSP type I is a superficial implantation of the embryo on the cesarean scar (CS) which develop towards the cervicoisthmic space or the uterine cavity. CSP type II is a deep implantation of the embryo into a CS defect growing towards the bladder, infiltrating the uterine myometrium, and bulging from the uterine serosa. CSP type II may result in uterine rupture and hemorrhage during the first trimester of pregnancy. The above two types of CSP are easily differentiated by ultrasound or MRI examination. Due to the high risk of life-threatening complications including massive hemorrhages/shock, uterine rupture with the potential necessity for hysterectomy in worst case scenario and maternal death, CSP needs a prompt accurate and proper diagnosis and management. However, termination of pregnancy is generally recommended. Routine transvaginal ultrasonography has been recommended in early pregnancy for patients who have previously undergone a cesarean delivery [7-9].

**The Pathogenesis and Risk Factors of CSP**

The causes and mechanism of CSP is unclear, Jurkovic et al. [3] hypothesized that the pathogenesis of CSP can be explained by the presence of uterine scar dehiscence and small scar defects after cesarean deliveries. A compromise of the decidua basal is and the nitabuch fibrinoid layer, which normally constitutes a barrier preventing trophoblast invasion into the scarred myometrium of the lower anterior uterine segment enables the concepts to invade the myometrium through this microscopic dehiscence or defect in the scar [3]. Such defects can also develop from the trauma of other uterine surgery for example; curettage, myomectomy, metroplasty, hysteroscopy and even manual removal of placenta. Seow et al. [10,11] showed a possible correlation between intrauterine device, pelvic inflammatory disease and CSP [2]. Recently Zhi-Da et al demonstrated that the increased expression of decidual integrin β3 and Leukaemia-inhibitory factor (LIF) in the cesarean scar might be associated with embryo implantation in cesarean scar, which might lead to a CSP; and the occurrence of CSP might be related to the changes of endometrial receptivity in local cesarean scar. Information on any correlation between the number of previous caesarean sections, indication of the cesarean scar pregnancy, surgical technique and subsequent CSP are inadequate [3,9,10-13].

**Clinical Presentation**

CSP may present as early as 5-6 weeks to 16 weeks 5 of gestational age. The clinical manifestations of CSP range from...
Diagnostic hysteroscopy and diagnostic laparoscopy allows direct cases where TVUS and color flow Doppler are inconclusive [22]. A technique which has a long acquisition time, and mostly used for diagnosis [9,19,20]. It is notable that MRI is a costly diagnostic adjunct to ultrasound scan, although not compulsory for the non-invasive, simple, and cheap.

Transvaginal ultrasound (TVUS) is the first-line diagnostic tool for CSP, following a positive chemical pregnancy test with serum human chorionic gonadotropin (beta-hCG). A report has shown a sensitivity of 86.4% [14] of TVUS combined with color, spectral, and power Doppler imaging. Three-dimensional (3D) ultrasonography is also being increasingly used as it allows studying of a confined area in detail [15,16]. The following diagnostic criteria have been proposed: empty uterus and cervical canal; development of the gestational sac or fetal pole with or without cardiac activity or identification of a mixed-echo mass in the anterior part of the cesarean scar.

Diagnosis

The diagnosis of CSP is based on a thorough history, including obstetric and surgical history, physical examination, laboratory and radiographic findings. The diagnosis of CSP is often difficult, and a false-negative diagnosis may result into major complications. A literature search identified 751 cases of CSP, 13.6% had been misdiagnosed as either spontaneous abortions in progress, cervical pregnancies or low intrauterine pregnancies. Transvaginal ultrasound (TVUS) is the first-line diagnostic tool for CSP, following a positive chemical pregnancy test with serum human chorionic gonadotropin (beta-hCG). A report has shown a sensitivity of 86.4% [14] of TVUS combined with color, spectral, and power Doppler imaging. Three-dimensional (3D) ultrasonography is also being increasingly used as it allows studying of a confined area in detail [15,16]. The following diagnostic criteria have been proposed: empty uterus and cervical canal; development of the gestational sac or fetal pole with or without cardiac activity or identification of a mixed-echo mass in the anterior part of the cesarean scar.

Differential Diagnosis

The differential diagnosis includes a cervicoisthmic pregnancy, or a spontaneous miscarriage in progress. A cervical pregnancy is extremely rare in patients with previous cesarean delivery. Therefore, the differential diagnosis of a cervical pregnancy is mainly in patients with no history of cesarean delivery, heavier bleeding, presence of a layer of healthy myometrium visible between the bladder and the gestational sac [19] and gestational sac present within the cervix, giving an hour-glass shape to the uterus with a ballooned cervical canal on ultrasound [2,17,21]. In cases of a spontaneous miscarriage in progress, volume of bleeding is often greater due to detachment of a failed chorionic sac that is visibly seen in the cervical canal on TVUS, and on color flow Doppler, with the sac appearing avascular [23]. A drastic fall in the serum β-hCG level is noticed in a miscarriage. Occasionally, CSP can be misdiagnosed as a trophoblastic tumour if ultrasound scan indicates no evidence of pregnancy within the uterus but detects high vascularised mixed echo mass infiltrating the myometrium in presence of high serum β-hCG level. Diagnosis of CSP is relatively easy and early in pregnancy, but as it advances, the disparity between CSP, cervical pregnancy and low implanted intrauterine pregnancy becomes more difficult [4,21].

Management

Management of CSP is controversial, no universal treatment guidelines have been established, and its management in daily clinical practice is still based on the available data obtained from a limited number of patients. Not less than 30 primary therapeutic approaches towards the management of CSP have been published in literature. The treatment options such as expectant, medical, and surgical management or a combination of both have been proposed [12]. There is no consensus on treatment strategy in relation to CSP type or thickness of the myometrium between the bladder and gestational sac. Systemic methotrexate, uterine artery embolization, dilatation and curettage (D&C), and hysteroscopy are the most frequently adopted first-line approaches for CSP.

The aim of classifying CSP prior to treatment is to decrease the risk of adverse complications based on the characteristics of CSP types. In patients with CSP type I, the goal behind the choice of treatment is to evade prolonged procedures, with the aim of reducing complications and treatment failures. For patients with CSP type II, the preservation of patient fertility and a decreasing the risk of massive blood loss should be the priorities [7]. Individualizing treatment according to the CSP subtype, gestational age, fetal viability, severity of symptoms, serum hCG levels and ultrasonography findings, yields substantial improvement in clinical outcome.

The prospect of expectant management is that the concepts will either be reabsorbed or expelled by itself against the risk of uterine rupture and hemorrhage or proceed to term. Available data on expectant management show that it is hardly ever successful, and when it does, the prognosis for an uneventful term pregnancy is poor with high cases of hysterectomies secondary to placenta previa/accreta, uterine rupture or life-threatening
massive hemorrhage [2,9,14,24]. Therefore, termination of pregnancy in the first trimester is usually recommended. At this gestational age, the embryo is soft and fragile, the depth of placental implantation and the risk of invasion of the bladder are also considerably less than in late pregnancy [16].

Systemic Methotrexate (MTX) administration is the least invasive treatment and has been widely used for stable patients but not effective for CSP compared with when used for tubal ectopic pregnancies. CSP has been shown to respond well in a dose of 50 mg/m² and beta-HCG level of less than 5000 mIU/ml [22-15]. This is appropriate for a woman who is not in pain, haemodynamically stable with an unruptured CSP of <8 weeks of gestation and a myometrial thickness <2mm between the CSP and the bladder. [9,25] Nevertheless, alternative treatment interventions are necessary when the β-hCG level is >6000 mIU/ mL. MTX has a short half-life of 10 hours. Multiple doses of MTX have a higher success rate of about 75% than single dose of MTX. The advantages of this treatment include preservation of fertility and evading the need for surgery with its associated risks and complications.

However, its effect to stop the heart beats requires many days, which may not happen. Therefore, a long period of follow-up for beta-hCG to return to normal levels and for the conceptus to resolve completely is needed. It may also lead to further growth of the fetus as well as vascularization of the sac thereby prolonging the time of treatment. A subsequent secondary treatment with a possibly high rate of complication may jeopardize the patient.

It can be debated whether systemic MTX is the treatment of choice as some investigators advocate for local injection of MTX into the gestational sac because, the impaired vascularization of the fibrous tissue surrounding the sac may impair the penetration of sufficient MTX into the fetal sac. In systematic review of 1647 patients, 559 patients treated with Systemic MTX only 8.7% of cases were successful [26]. Another review of 751 showed a 62.1% rate of complication when MTX was used alone [12]. Secondary treatment was dilatation and curettage, uterine artery embolization, hysterectomy, and transcervical sonography-guided intragestational MTX. Systemic MTX as a single treatment of choice should generally be avoided. Multiple doses of systemic MTX may cause side effects such as nausea, vomiting, elevated hepatic enzymes, and bone marrow suppression.

Direct local injection of methotrexate into the amniotic cavity of a CSP under ultrasound guidance produce excellent outcomes as it achieves a high concentration locally and therefore interrupts the pregnancy more rapidly than systemic administration of the drug. But normalization of hCG levels and shrinkage of the sac still takes long with this treatment modality. Besides, this route has no added advantage over systemic administration with regard to serum drug level and systemic toxicity. Other feticide/embryocides that have been used include potassium chloride [19], hyperosmolar glucose [20] and crystalline trichosanthis .Combined regimens have been described by many authors including; injecting potassium chloride into the gestational sac followed by methotrexate [27], simultaneous intravenous and intra-amniotic injections of MTX [28]. Complication rate is about 9.6% [12,18].

Uterine artery embolization (UAE) is another nonsurgical treatment for CSP used as a primary treatment but should be used sparingly or not at all. A recently published expert review stated that UAE alone had a complication rate of 80%, and thus, should be used as an auxiliary method for uncomplicated cases of CSP [12,26]. Among CSP patients treated with UAE, 63-73% require curettage to stop vaginal bleeding or to remove the retained products of conception [8,29,30]. UAE has a number of advantages such as blockage of blood supply to the gestational sac, which causes embryo ischemia, hypoxia, atrophy and finally necrosis, and at the same time reduces the risk of bleeding during curettage. However, in the case of excessive bleeding, UAE can accurately detect and embolize the pelvic arteries to stop bleeding. As an embolic agent, gelatin sponge can embolize arteries effectively and at the same time be absorbed naturally 14-21 days later, so that the blood flow of the uterus can recover and uterine function is not affected [31-34]. In view of these benefits of UAE, combined therapeutic approach should be considered in order to achieve optimal results.

Uterine curettage as a primary treatment for CSP can lead to severe hemorrhage that results from gestational sac rupture and myometrial disruption. The vessels exposed by curettage bleed because the thin scar tissue is unable to contract and contain the bleeding. Arslan et al. [35] described the first case of CSP that was successfully treated with D&C alone, but failed with complications in some other cases. These patients were subsequently treated with different methods such as hysterectomy, systemic MTX or excision of the mass. Some authors argue for suction curettage under ultrasound guidance in selected cases of gestational age ≤7 weeks and myometrial thickness ≤3.5 mm anterior to the CSP [35,36]. Prolonged beta-hCG follow up can be a major drawback. A recent review demonstrated D&C alone treatment of CSP with complication rate of 63% [12]. Therefore, it would be lucid to avoid D&C as a first-line approach. Additionally, D&C as a first-line approach is associated with infertility and poor obstetric outcome irrespective of whether it is successful or not [12].

Successful treatment of CSP by operative hysteroscopy and suction curettage has been described in various studies [39-43]. A systematic review demonstrated hysteroscopy as an optimal first-line approach for CSP with a lower complication rate (18.2%). It can be utilized for the CSP that grows inwards toward the uterine cavity. Hysteroscopy is a minimally invasive technique conducted under direct visualization or Transabdominal ultrasound. The gestational sac is dissected free of the uterine wall through a natural orifice, and hemostasis can be achieved with electro coagulation. A balloon catheter may be placed postoperatively for compression hemostasis and wound surface drainage. Other advantages of this technique over systemic MTX and UAE are the avoidance of toxicity, shorter duration of resolution, and rapid return to fertility. However, the procedure requires general anesthesia, well trained personnel, and operative equipment.

Surgical intervention is another reliable treatment option for CSP. Hysterectomy with either laparotomy, laparoscopy and transvaginal route is quite successful with low failure rates. A systematic review [44] demonstrated that hysterotomy successfully treated 92% of the reviewed CSP cases, and hysterectomy was
required in only 2% of the cases. Moreover, the ability to achieve a subsequent term pregnancy was found to be related to successful hysterotomy. Surgical treatment has a number of advantages such as one-time lesion clearance and instantaneous repair of the scar, removes the microtubular tracts and thus reduces the risk of recurrence followed by a rapid return of the beta-hCG to normal level within 1-2 weeks, preservation of patient fertility, and no undesirable effect on menstruation [6,9,20]. Laparotomy followed by wedge resection of the lesion should be considered in women who present too late or if facilities and expertise for operative endoscopy are not available. Laparotomy is necessary in cases where uterine rupture is established or strongly suspected. This approach, however, inflicts a larger surgical wound, longer hospital stay and recovery time, with an increased risk of a future placenta praevia/accreta [45]. Laparoscopic wedge resection of CSP is justified in hemodynamically stable women who have deeply implanted gestational sacs growing toward the abdominal cavity and bladder. Reports suggest that laparoscopic evacuation of CSP is a safe and less time-consuming procedure but requires operative skills and equipment [13,31,45,46]. Transvaginal surgery is a novel minimally invasive therapy best for CSP Type II. A retrospective analysis of 25 patients with CSP Type II conducted who received transvaginal surgical treatments had successful surgery, without intraoperative or postoperative complications [47]. Robotic assisted laparoscopic removal of residual cesarean ectopic pregnancy was also reported by Schmitt et al. [48].

High-Intensity Focused Ultrasound Ablation (HIFU)

This procedure can be performed with ablation alone or in combination with hysteroscopic D&C [44]. The initial procedure is performed under conscious sedation. A transducer produces the therapeutic energy required. Real-time ultrasound is used to target the area of the gestational sac and monitor the response. Additional D&C is performed under general anesthesia. This novel treatment modality described in two high-quality case series had a success rate of 100% with no complications and no additional treatment warranted. [49-50]. Since systemic MTX injections, dilatation and curettage, and UAE are treatments that have all demonstrated high complication rates previously, combining therapeutic approaches should be considered when selecting the treatment options. The following Combinations have been described in literature, with improved outcome and are more frequently used at present.

1. UAE+ D&C, without MTX.

   Overall this treatment modality was efficient with additional treatment needed in only 6.4% and severe complications seen in 3.4% [23]. A systematic review by Timor-Tritsch et al demonstrated a complication rate of 29.5% [12].

2. UAE+ D&C + MTX

   Additional treatment was needed in 31.4 % because of treatment failure [23].

3. UAE + D&C + Hysteroscopy

   This modality has a high success rate of 95.4% and a very low complication rate of 1.2% [23].

4. Systemic MTX + D&C

   Intramuscular methotrexate and D&C in combination had a complication rate of 86% [12].

5. UAE+ hysteroscopic surgery

   In a retrospective study of 67 patients with exogenous CSP by who underwent selective UAE combined with hysteroscopic surgery, treatment was successful without complications when the uterine scar tissue thickness was >3 mm. For uterine scar thickness <3mm, 3 cases required secondary laparoscopic or open surgery, after surgery, 7 patients received a second hysteroscopic operation [49].

6. Intra-arterial MTX + UAE

   followed by combined laparoscopy and hysteroscopy. Intrarterial MTX + UAE+ combined laparoscopy and hysteroscopy 25 patients, 100% success rate. Blood loss less than 200ml [50].

7. UAE combined with local MTX or systemic MTX

   UAE combined with local MTX infusion has been used extensively in recent years, and it has been suggested that the effects of MTX are synergistic to UAE [50,51].

8. Systemic MTX+hysteroscopy

   5 patients in the review by Timor-Tritsch et al, all had complications [12].

Hysterectomy

Although hysterectomies have been reported in the literature as primary procedure in a few cases, it is generally recommended as the last resort when other treatment modalities fail. This shows that CSP is a potentially serious condition despite advances in many of the diagnostic techniques and therapeutic measures [2,45]. Risk of recurrence. The risk of reoccurrence is about 1% [53-59].

Conclusion

CSP are rare form of ectopic pregnancies that can result into life threatening complications if not diagnosed early and managed aggressively. The most efficient and safe treatment modality for CSP is yet to be determined, but five approaches are recommended depending on availability, hemodynamic status of the patient, beta-hCG levels, imaging features, the desire for future pregnancy and the surgeon’s skill . Systemic MTX, UAE and D&C as a single treatment should be avoided due to the high complication rate [60-72].

References


